Feedback / Questions
BHV-1510 - Biohaven
https://www.prnewswire.com/news-releases/biohaven-presents-clinical-safety-and-efficacy-data-for-bhv-1510-a-next-generation-trop2-antibody-drug-conjugate-in-combination-with-cemiplimab-at-the-2025-european-society-for-medical-oncology-esmo-immuno-oncology-congress-302638503.html
Dec 11, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next